How does micro-dosing melatonin differ from standard doses in circadian
Research into melatonin dosing indicates that while standard doses (typically 2–10 mg) are often used for chronobiotic effects, lower doses in the 0.1–0.5 mg range are intended to more closely mimic endogenous physiological levels[1][2]. Pharmacokinetic studies in older adults show that both low (0.4 mg) and high (4.0 mg) doses exhibit linear kinetic behavior, with similar elimination half-lives and times to reach maximum concentration[3]. However, high-dose formulations carry a greater risk of maintaining supraphysiological melatonin levels into the post-awakening period, which may influence next-day alertness[4]. Evidence regarding the clinical effectiveness of melatonin for insomnia remains mixed, with some studies showing improvements in sleep efficiency or latency and others reporting no significant difference compared to placebo[5].
The following table summarizes key findings regarding melatonin dosing and sleep outcomes in older adults.
| Finding | Study design | Population | Outcome | Source | Year |
|---|---|---|---|---|---|
| Low (0.4 mg) and high (4.0 mg) doses show linear pharmacokinetics | RCT (Pharmacokinetic sub-study) | Older adults (n=27) | Similar half-life and Tmax | nih[6] | 2013 |
| High doses (4.0 mg) lead to prolonged supraphysiological levels | RCT (Pharmacokinetic sub-study) | Older adults (n=27) | Elevated levels >10 hours | nih[7] | 2013 |
| Mixed evidence for sleep efficiency and latency improvements | Systematic Reviews/RCTs | Adults with insomnia | Variable sleep outcomes | nih[8] | 2022 |
Would you be interested in learning more about the potential cytoprotective effects of high-dose melatonin in older adults with chronic comorbidities?
Crea el teu compte per conservar aquesta resposta i continuar-hi més tard.
Veiem alternatives:
- Modifica la consulta.
- Inicia un nou fil.
- Elimina les fonts (si s'han afegit manualment).
